Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
50,000
Stocks News & Analysis
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
stocks
SpaceX jumps 19% in debut, but hurdles lie ahead
Pre-IPO holders could start selling later this summer, and earnings will be an important test.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.00 | 14.60 | 0.16% |
| CAC 40 | 8,435.26 | 84.39 | 1.01% |
| DAX 40 | 24,921.35 | 286.05 | 1.16% |
| Dow JONES (US) | 51,202.26 | 353.51 | 0.70% |
| FTSE 100 | 10,485.06 | 13.34 | 0.13% |
| HKSE | 24,842.67 | 124.57 | 0.50% |
| NASDAQ | 25,888.84 | 79.18 | 0.31% |
| Nikkei 225 | 69,317.50 | 3,297.46 | 4.99% |
| NZX 50 Index | 13,360.59 | 33.28 | -0.25% |
| S&P 500 | 7,431.46 | 37.16 | 0.50% |
| S&P/ASX 200 | 8,914.00 | 7.00 | 0.08% |
| SSE Composite Index | 4,096.47 | 64.96 | 1.61% |